MJ33-OH is a metabolite of MJ33, which is an active site-directed, specific, competitive, and reversible inhibitor of phospholipase A2 (PLA2). MJ33 inhibits the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6. In vivo, MJ33 (0.5 μM/kg, administered via tail vein 24 h before MCAO) significantly blocks the increase of IL-1β, IL-17, and IL-23 in rats induced by Prdx6 siRNA treatment. Combined treatment with Prdx6 siRNA and MJ33 significantly downregulates the mRNA and protein expression of NF-κB, iNOS, and COX-2 compared to Prdx6 siRNA treatment alone.